Home › Researcher directory › Mark Lebwohl
Mark Lebwohl
Affiliation : Icahn School of Medicine at Mount Sinai
- 11Publications (affiliation in the United States)
- 1449Total publications
- 57348Citations
- 121h-index
Research profile
Mark Lebwohl has 11 indexed publications (2021–2025). Their work appears mainly in “Future Rare Diseases”, “Journal of the American Academy of Dermatology” and “International Journal of Dermatology”. Their most cited article, “Trial of Spesolimab for Generalized Pustular Psoriasis” (2021), has been cited 359 times. 6 of these publications date from the last three years of activity. Their work is co-authored with at least 12 researchers, including institutions in France, Malaysia, Taiwan, United Kingdom.
Is this you? Get your research seen
Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.
Create my free profile Add my publicationsResearch areas
- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Nonmelanoma Skin Cancer Studies
- Skin Protection and Aging
Publications (11)
- Psoriasis in People With Skin of Color: An Evidence‐Based Update
- Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study
- Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil ™ 2 study
- Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
- Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
- The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity
- 33547 Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scale for assessing severity of GPP
- Spesolimab Treatment for People with Flares of Generalized Pustular Psoriasis: A Plain Language Summary of the Effisayil™ 1 Study
- Trial of Spesolimab for Generalized Pustular Psoriasis
- Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
- 26590 Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis with an acute flare
Publication venues
- Future Rare Diseases × 2
- Journal of the American Academy of Dermatology × 2
- International Journal of Dermatology × 1
- Video Journal of Biomedicine × 1
- The Lancet × 1
- Dermatology × 1
Publications per year
- 20252
- 20241
- 20233
- 20222
- 20213
Collaborations
Partner institutions : National Taiwan University Hospital · Monash University Malaysia · Inserm · Université Paris Cité · Sultanah Aminah Hospital
Co-authors’ countries : France · Malaysia · Taiwan · United Kingdom
Co-authors
- Milan J. Anadkat
- Bruce E Strober
- Sushmita Rajeswari
- Kenneth B. Gordon
- Kristina Callis Duffin
- David Hall
- David B. Hall
- Diamant Thaçi
- Junko Takeshita
- Tsen‐Fang Tsai
- Andrew F Alexis
- Mio Nakamura
Bibliographic data from OpenAlex (open database).
Why choose Dzcademia?
Profiles, articles and conference contributions: give your research a structured public presence. Integrated metadata help search engines and AI assistants identify your work and understand its references.
Comment with Google
Sign in with Google to comment directly on this page.